By Dengyuemed International Business Department For decades, global oncology treatments have relied primarily on traditional modalities such as small-molecule inhibitors, antibody therapies, and cell therapies. However, challenges such as drug resistance, undruggable targets, and ...Learn More

By: DengYue International Business DivisionTen years ago, China was known primarily as a supplier of APIs and low-cost generic medicines to the world. Today, if someone tells you that China is developing, manufacturing, and exporting world-class oncology drugs, biologics, ...Learn More

In the realm of biotechnology and molecular biology, the integrity of pharmaceuticals is paramount, directly impacting research outcomes, clinical trials, and public health. While China's regulatory framework for drugs has advanced significantly, counterfeit ...Learn More

By DengYueMed International Business DivisionToday, DengYueMed shares key commercial insights into China’s EGFR small-molecule targeted therapy market with international buyers and distribution partners. Drawing on the latest publicly available data, we analyzed the sales trends ...Learn More

As the global pharmaceutical industry transitions into a new era of innovation and precision medicine, the significance of Formulation Development has become increasingly prominent. It not only relates to the safety, efficacy, and stability of drugs but also serves as the critical ...Learn More